Seth Lederman
CEO, Tonix Pharmaceuticals
Throughout his career, Lederman has been a pioneer in the field of drug discovery. Currently serving as the CEO of Tonix Pharmaceuticals, he leads a team of scientists and medical professionals addressing the unmet needs of patients with painful neurological conditions such as fibromyalgia, long COVID, and migraine. Lederman has also played a key role in spearheading Tonix's collaborations with Boston Children's Hospital, Columbia University, and Kansas State University. Additionally, Lederman was considered instrumental in Tonix's acquisition of three facilities located in Maryland, Massachusetts, and Montana to support the R&D and manufacturing of drug candidates in the company's pipeline.
Before joining Tonix, Lederman served as a professor at Columbia University College of Physicians and Surgeons and as a rheumatologist at Columbia Presbyterian Hospital. During this time, his groundbreaking research in molecular immunology led to the discovery of the CD40 ligand and its role in T-cell helper function. This discovery, in collaboration with Biogen and UCB, led to the development of therapeutic candidates for autoimmune diseases and organ transplant rejection.
Lederman has also worked as an attending physician in the Edward Daniels Arthritis and Autoimmunity Clinic on the Medical Service at Columbia Presbyterian Hospital for several years. He holds an MD from Columbia University's College of Physicians and Surgeons and an AB from Princeton in Chemistry cum laude.
